Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,159.67 +31.88 (+0.62%) Dow
38,820.65 +144.97 (+0.37%) Nasdaq
16,261.04 +104.71 (+0.65%) Bitcoin USD
64,107.04 +220.87 (+0.35%) CMC Crypto 200
1,379.08 +66.45 (+5.06%)
Catalent, Inc. (CTLT.MX)
| Previous close | 823.19 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 823.19 - 823.19 |
| 52-week range | 568.00 - 868.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 148.976B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -22.14 |
| Earnings date | 17 May 2024 - 21 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters SG
Deals of the day-Mergers and acquisitions
** Sony Pictures Entertainment and private equity firm Apollo Global Management on Wednesday submitted a $26 billion offer for Paramount Global but have yet to receive a response as of Friday, according to a person familiar with the matter. ** L Catterton, a private equity firm backed by French luxury group LVMH , said on Friday it had succeeded in securing enough shares in luxury shoe maker Tod's to take it private in agreement with the Italian group's main shareholder, the Della Valle family.
Business WireCatalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.
Business WireCatalent, Inc. Reports Second Quarter Fiscal 2024 Results
SOMERSET, N.J., February 09, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.
